<DOC>
	<DOCNO>NCT01472016</DOCNO>
	<brief_summary>This Phase 1/1b open-label study evaluate safety , pharmacokinetics ( PK ) , preliminary efficacy ABT-700 subject advance solid tumor may MET amplification c-Met overexpression . ABT-700 , previously know h224G11 publication , anti-c-Met antibody . The early clinical development plan ABT-700 base activity demonstrate preclinical model . Up 124 subject enrol .</brief_summary>
	<brief_title>Study ABT-700 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Subject advance solid tumor ; Doseexpansion : evidence MET gene amplification . Subject must disease : ) amenable surgical resection , b ) progress recur despite standard therapy , c ) fail respond standard therapy , ) effective therapy exists . Subject tolerate must eligible approve therapeutic option know survival advantage . Subjects enrol combination therapy phase must satisfy inclusion criterion also follow : Subjects must inoperable , locally advanced metastatic cancer eligible receive docetaxel FOLFIRI/cetuximab erlotinib combination ABT700 . Subject receive anticancer therapy include chemotherapy , immunotherapy , radiation therapy , immunotherapy , biologic , investigational therapy within period 21 day , herbal therapy within 7 day prior first dose ABT700 . Subjects uncontrolled metastasis central nervous system . Subjects brain metastasis eligible provide show clinical radiographic stable disease definitive therapy use steroid least 1 month prior first dose ABT700 . Subject unresolved adverse event &gt; Grade 1 prior anticancer therapy except alopecia anemia . Subject major surgery within 21 day prior first dose ABT700 . Subjects enrol combination therapy phase must meet exclusion criterion must eligible receive docetaxel FOLFIRI/cetuximab erlotinib per current prescribing information , discretion Investigator . Subjects KRas mutationpositive colorectal cancer exclude receive FOLFIRI/cetuximab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>c-Met overexpression</keyword>
	<keyword>MET amplification</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>h224G11</keyword>
</DOC>